Results 251 to 260 of about 47,774 (288)
Some of the next articles are maybe not open access.
Delivery systems for antisense oligonucleotides
Pharmacology & Therapeutics, 2000In vitro, the efficacy of the antisense approach is strongly increased by systems delivering oligodeoxyribonucleotides (ODNs) to cells. Up to now, most of the developed vectors favor ODN entrance by a mechanism based on endocytosis. Such is the case for particulate systems, including liposomes (cationic or non-cationic), cationic polyelectrolytes, and ...
C, Garcia-Chaumont +4 more
openaire +2 more sources
Pharmaceutical Research, 1999
This review critically examines current understanding of the kinetics and biodistribution of antisense oligonucleotides, both at the cellular level and at the level of the intact organism. The pharmacodynamic relationships between biodistribution and the ultimate biological effects of antisense agents are considered.
R L, Juliano +4 more
openaire +2 more sources
This review critically examines current understanding of the kinetics and biodistribution of antisense oligonucleotides, both at the cellular level and at the level of the intact organism. The pharmacodynamic relationships between biodistribution and the ultimate biological effects of antisense agents are considered.
R L, Juliano +4 more
openaire +2 more sources
Self-Assembled Double-Bundle DNA Tetrahedron for Efficient Antisense Delivery
ACS Applied Materials & Interfaces, 2018 DNA nanostructures are promising biomaterials capable of arranging multiple functional components with nanometer precision. Here, a double-bundle DNA tetrahedron is rationally designed to integrate with antisense oligonucleotides silencing proto-oncogene
Qiao Jiang, Lin He, Pengfei Zhan
exaly +2 more sources
Oral Delivery of Antisense Oligonucleotides in Man
Journal of Pharmaceutical Sciences, 2008Treatment of systemic disease with phosphorothioate antisense oligonucleotides (PS ASOs) has been accomplished using local or parenteral routes of administration to date. This report describes, for the first time, the effective oral delivery of a second generation oligonucleotide where significant milligram amounts of intact drug are absorbed in human ...
Lloyd G, Tillman +2 more
openaire +2 more sources
Nanoparticulate systems for the delivery of antisense oligonucleotides
Advanced Drug Delivery Reviews, 2001Antisense oligonucleotides are molecules that are able to inhibit gene expression being therefore potentially active for the treatment of viral infections or cancer. However, because of their poor stability in biological medium and their weak intracellular penetration, colloidal drugs carriers such as nanoparticles were developed for the delivery of ...
G, Lambert, E, Fattal, P, Couvreur
openaire +2 more sources
Delivery of antisense oligonucleotides to PC12 cells
Neuroscience Research, 2002Optimal experimental conditions for the delivery of phosphodiester or phosphorothioate antisense oligonucleotides (P-ASO/S-ASO) to PC12 cells were determined. Fluorescently labeled P-ASO or S-ASO were transfected to PC12 cells and the uptake of antisense, free or entrapped in liposomes, was monitored by confocal and fluorescent microscopy.
Rosalinda, Acosta +3 more
openaire +2 more sources
Delivery of Antisense Oligonucleotides to the Vascular Wall
2003Antisense oligonucleotides are short segments of synthetic DNA designed to contain sequences of bases complementary to the DNA or RNA of a particular target gene of interest. By binding to the target, the antisense oligonucleotides can prevent translation of the gene into protein via different mechanisms including destruction of the AS-ODN-nucleic acid
Holt, Cathy M +4 more
openaire +3 more sources
Delivery of antisense oligonucleotides to neuroblastoma cells
NeuroReport, 2000pH-Sensitive liposomes composed of dioleoylphosphatidylethanolamine and cholesterol hemisuccinate (3:2 mol/mol) were applied in delivery of antisense oligodeoxynucleotides (asODN) into NG 108-15 neuroblastoma and glioma cells. Fluorescently labelled asODN were entrapped in liposomes by a modified freeze-thawing method (20% encapsulation efficiency ...
N, Skalko-Basnet, M, Tohda, H, Watanabe
openaire +2 more sources
Targeted delivery of antisense oligonucleotides in cancer
Journal of Controlled Release, 2001Formulations of antisense oligonucleotides (asODNs) against c-myb or c-myc protooncogenes have been prepared by a new technique that sequesters cationic lipid in the interior of a lipid particle. This technique results in high loading efficiency for the asODNs, small particle size and good stability.
F, Pastorino +3 more
openaire +2 more sources
Antisense Technology: Selection and Delivery of Optimally Acting Antisense Oligonucleotides
Journal of Drug Targeting, 1998AbstractAntisense technology has increasingly become a reality. It's objective is simple: to inhibit gene expression in a highly sequence-specific and selective manner. The technology has come to encompass three distinct strategies: antigene and antisense oligonucleotides (ODNs) and ribozymes.
openaire +2 more sources